Ostiban 150 mg (Tablet)
1 tablet kit: ৳ 510.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Ibandronic acid |
| Company | Eskayef pharmaceuticals ltd |
Title
- Ostiban
Categories
- Medicine
- Healthcare
- Pharmaceutical
Description
- Indicated for the treatment of osteoporosis in women (specially postmenopausal)
- Prevention of osteoporosis in women (specially postmenopausal)
- Prevention and treatment of osteoporosis in men
- Pharmacodynamic action is inhibition of bone resorption
- Prevents experimentally induced bone destruction caused by cessation of gonadal function, retinoids, tumors or tumor extracts
- Selective action on bone tissue based on high affinity for hydroxyapatite
- Reduces bone resorption with no direct effect on bone formation
- Reduces the elevated rate of bone turnover towards premenopausal levels
- Highly potent bisphosphonate belonging to the nitrogen-containing group
- Recommended dosage is one 150 mg film-coated tablet once a month
- Should be taken 60 minutes before the first food or drink of the day
- Patients should not lie down for 60 minutes after taking the tablet
- Tablets should be swallowed whole with a full glass of plain water
- Patients should not chew or suck the tablet
- Patients should receive supplemental calcium or vitamin D if dietary intake is inadequate
- Interferes with the absorption of calcium supplements, antacids, and some oral medications containing multivalent cations
- No interaction potential with tamoxifen or hormone replacement therapy (estrogen)
- No clinical significance of drug interactions
- Contraindicated in patients with known hypersensitivity to ibandronic acid or to any of the excipients
- Contraindicated in patients with uncorrected hypocalcemia
- Contraindicated in patients with abnormalities of the esophagus which delay esophageal emptying
- Contraindicated in patients who are unable to stand or sit upright for at least 60 minutes
- Main side effects include dyspepsia, nausea, diarrhea, abdominal pain, muscle aches, headaches, dizziness
- Not recommended for use during pregnancy or lactation
- Hypocalcemia and other disturbances of bone and mineral metabolism should be effectively treated before starting therapy
- Use with caution in patients with active upper gastrointestinal problems
- Risk of severe esophageal adverse experiences
- Risk of gastric and duodenal ulcers
- Osteonecrosis of the jaw has been reported in patients treated with bisphosphonates
- No dosage adjustment needed for patients with renal or hepatic impairment
- No dosage adjustment needed for elderly patients
- Not established for patients less than 18 years old
- No specific information available on the treatment of overdosage
- Belongs to the therapeutic class of bisphosphonate preparations
- Recommended storage conditions: below 30°C temperature, away from light & moisture, keep out of the reach of children
Dimensions
- 150 mg tablet
Color Options
- Film-coated tablet
Functions
- Inhibition of bone resorption
- Prevention and treatment of osteoporosis
- Reduction of bone turnover
- Increased bone mass
Materials
- Ibandronic acid
- Hydroxyapatite
- Excipients in the tablet
Technical Specifications
- Highly potent bisphosphonate belonging to the nitrogen-containing group
- No clinical significance of drug interactions
- No specific information available on the treatment of overdosage
Design Elements
- Film-coated tablet
Usability Features
- Recommended dosage is one 150 mg tablet once a month
- Tablets should be swallowed whole with a full glass of plain water
- Patients should receive supplemental calcium or vitamin D if dietary intake is inadequate
- No specific information available on the treatment of overdosage